Prescription / GLP-1

Peptide Telehealth: How Legal Prescribing Actually Works

Peptide telehealth: who can legally prescribe which peptides online, what a real consult requires, and why an unapproved research peptide cannot be prescribed.

Written bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio

Published September 24, 2026Updated October 3, 2026

The short version

A legitimate telehealth peptide consult can only end in a prescription for an FDA-approved drug, or a lawful compounded version of one made under FDA rules. A licensed clinician has to screen you first. No telehealth clinic can lawfully prescribe a "research use only" peptide such as BPC-157, however it markets itself. Those are not legal prescription items at all, in person or online.

Telehealth removes the office visit, not the licence, the screening, or the prescription requirement.
A prescriber must be licensed in the state where the patient is located when the prescription is written.
A clinic can prescribe only FDA-approved drugs and lawfully compounded versions of them. Research peptides are neither.
The red flags FDA has published for online GLP-1 sellers apply to telehealth "peptide clinics" generally.

Telehealth peptide prescribing means getting a prescription peptide, most commonly a GLP-1 medicine, after a video or asynchronous consult instead of an in-person office visit. The legal requirements stay the same. A licensed clinician still has to screen you, the thing prescribed still has to be a legal drug, and a licensed pharmacy still has to dispense it.

“Peptide clinics” most often fail on the second requirement. Telehealth can legally deliver a prescription for an FDA-approved drug, or in some cases a lawfully compounded version of one. It cannot turn an unapproved research peptide into a legal prescription item, however the consult is run.

Who can prescribe what

Two separate things have to be true before a telehealth prescription for a peptide is legal.

The prescriber has to be licensed to prescribe, in the state the patient is in. A doctor, nurse practitioner or physician associate practising telehealth generally needs a licence valid where the patient is physically located at the time of the visit. The state where the clinic’s office sits is not enough. A clinic that never asks which state you are in cannot be verifying this.

The thing being prescribed has to be a legal drug. For peptides, that narrows sharply to two categories:

An FDA-approved drug, for example a semaglutide or tirzepatide product with its own FDA approval, under its approved brand name and label.
A compounded version of a drug, made lawfully. FDA describes compounding as a licensed pharmacist or physician (or, at an outsourcing facility, someone supervised by one) combining, mixing or altering ingredients. The aim is to tailor a medication to an individual patient. Compounded drugs are not FDA-approved themselves. The agency does not review them for safety, effectiveness or quality before they reach a patient.

A research peptide such as BPC-157 or a “GLP-1 blend” sold without a brand name fits neither category. It has no FDA approval, and most research peptides are not on FDA’s list of bulk substances that may lawfully go into a compounded drug. There is no legal drug to prescribe.

What a legitimate consult involves

A consult that properly screens you has these parts:

A real intake. Medical history, current medications, relevant conditions. Not a three-question form built to qualify everyone.
A licensed clinician reviewing it. Not an algorithm deciding alone, and not a salesperson with no clinical licence.
A prescription tied to an approved drug or a lawful compounded version of one. Not a “research peptide protocol.”
Dispensing through a licensed pharmacy. The medicine should arrive from a pharmacy, not a vendor shipping unlabelled vials.
A way to reach a clinician after you start. Side effects and dose questions need a licensed person on the other end, not a support inbox.

FDA has published a telehealth red-flag list. It was written for the compounded and unapproved GLP-1 market, and it applies to any telehealth peptide seller:

FDA’s advice is to get a prescription from your doctor and fill it at a state-licensed pharmacy.

Compounded GLP-1s over telehealth

Compounded semaglutide and tirzepatide are common on telehealth “peptide clinic” sites. Compounding can be lawful, and FDA’s framework allows two paths:

Section 503A pharmacy compounding. A state-licensed pharmacist or physician compounds for an identified individual patient, generally against a patient-specific prescription.
Section 503B outsourcing facilities. These are registered with FDA, inspected on a risk-based schedule, and held to current good manufacturing practice requirements the way a drug manufacturer is.

Neither path makes the resulting product FDA-approved. A patient still needs a prescription from a licensed prescriber, not a marketing page offering “compounded semaglutide” to anyone who fills out a form.

FDA has published specific concerns about the compounded and grey-market GLP-1 supply:

dosing errors
counterfeit product
unapproved salt forms substituted for the approved active ingredient
fraudulent labelling that names pharmacies that do not exist

A telehealth clinic offering compounded GLP-1s should be able to name the licensed pharmacy or outsourcing facility filling the prescription. If it cannot, that is the same red flag as any other unverifiable supply chain.

FDA turned to telehealth sellers directly in 2026. On 6 February it said it intends to restrict the GLP-1 ingredients used in compounded drugs that are mass-marketed as alternatives to approved ones. On 3 March it announced warning letters to 30 telehealth companies. The letters were mainly for implying that their compounded products were the same as approved drugs, and for branding products in a way that hid who compounded them.

For the legal routes to each drug, with the manufacturers’ self-pay prices, see tirzepatide online and semaglutide online.

US legal status - FDA-approved · prescription only

Branded GLP-1 products such as Ozempic, Wegovy, Mounjaro and Zepbound are FDA-approved prescription drugs. A compounded version of the same molecule is not itself FDA-approved, even when the compounding is lawful - it is a different regulatory category with its own rules.

Why a clinic cannot lawfully prescribe a research peptide

“Research use only” is a labelling category, and it gives no route to human prescribing. A vial marked that way is sold outside any FDA review of its safety, effectiveness or quality for human use. Compounded drugs share that gap, but they at least have a lawful compounding path.

Two independent facts rule out a legal research-peptide prescription:

It is not an FDA-approved drug. Nothing sold as “research use only” has gone through FDA’s approval process.
Most research peptides are not eligible for lawful compounding either. Under the FD&C Act, a bulk substance may go into a compounded drug only if it meets one of three conditions. It complies with an applicable USP/NF monograph, it is a component of an already-approved drug, or it appears on FDA’s list of substances added specifically for 503A compounding. FDA reviews candidate substances, including some research peptides, against that bar. Being reviewed is not the same as being added.

A clinic that prescribes a compound meeting neither condition has not found a legal path around FDA approval. It has prescribed something that is not a lawful prescription drug.

Retatrutide: a current example

Retatrutide is a common search alongside “peptide telehealth” because it is the newest widely discussed GLP-1-class peptide.

FDA states that retatrutide “cannot be used in compounding under federal law.” The same statement adds two points. Retatrutide is not a component of an FDA-approved drug, and it has not been found safe and effective for any condition. That rules out both legal paths at once.

So a US telehealth clinic cannot lawfully sell or prescribe retatrutide for human use, however the consult is framed. FDA has not reviewed its safety or effectiveness, which is a narrower claim than saying it is unsafe.

Common questions

Can a telehealth clinic legally prescribe BPC-157 or other research peptides?

No. Research peptides such as BPC-157 are not FDA-approved drugs and are not on FDA's list of substances eligible for compounding under section 503A. A prescription needs a legal drug to prescribe. Selling one after an online "consult" does not make the product lawful.

Does a telehealth doctor need to be licensed in my state?

Generally, yes. The prescriber needs a licence valid in the state where the patient is physically located when the prescription is written, not just where the clinic is based.

What makes a telehealth peptide consult legitimate?

It has five parts. A real intake and medical history. A licensed clinician reviewing it, not an algorithm alone. A prescription only for an FDA-approved drug or a lawfully compounded version of one. Dispensing through a licensed pharmacy. A way to reach a clinician afterward.

Are compounded semaglutide or tirzepatide legal over telehealth?

Only under specific conditions: generally a patient-specific prescription filled by a licensed pharmacist or physician, or an FDA-registered outsourcing facility. FDA has published concerns about the compounded GLP-1 market, including dosing errors and counterfeit product. Its shortage-era allowances for compounding both drugs ended in 2025. In February 2026 it said it intends to restrict the ingredients used in mass-marketed compounded copies.

Can I buy retatrutide online in the USA?

Not lawfully as a prescription medicine. Retatrutide has no FDA approval for any condition, and FDA states it cannot be used in compounding under federal law. There is no legal drug for a US telehealth clinic to prescribe or sell.

Is retatrutide safe?

FDA has not found retatrutide safe and effective for any condition, because it has not been through FDA review. It is an investigational drug in company-run trials, not an approved medicine.

How can I tell if a telehealth peptide provider is legitimate?

Look for a real medical intake and a licensed clinician (not an algorithm or salesperson) reviewing it. The prescription should be limited to an FDA-approved drug or a lawfully compounded version of one, dispensed through a licensed pharmacy, with ongoing access to that clinician. A site that skips any of these is not a substitute for that judgement, whatever its marketing or reviews say.

What is the most legit peptide website?

This site does not name, rank or recommend any seller. For an FDA-approved peptide drug, the lawful route is a licensed prescriber and a licensed pharmacy, not a website. For a compounded version, the pharmacy or outsourcing facility must operate under FDA compounding rules. A research-labelled peptide sold online is not lawfully a human-use product, whichever site sells it, because "research use only" is a legal restriction, not a marketing label. See my peptide vendor checklist and my guide to reading a certificate of analysis for what to check before buying anything.

Which is the most reputable peptide company?

This site does not name, rank or recommend any company. Reputation claims on a seller's own site are not independent evidence of legality or quality. What matters is the legal route: an FDA-approved drug through a licensed prescriber and pharmacy, or a compounded drug made under FDA's 503A or 503B rules. A company selling a research-labelled peptide directly to consumers for human use is outside both routes, however it markets itself. My peptide vendor checklist and my guide to reading a certificate of analysis cover what independent checks are available.

Do I need a doctor to prescribe peptides?

For a peptide medicine, yes. FDA-approved peptide drugs such as semaglutide and tirzepatide need a prescription, and so do lawfully compounded versions of them. It must come from a licensed clinician (a doctor, nurse practitioner or physician associate), generally licensed in the state you are in. Research peptides such as BPC-157 are different. As of this writing they are neither FDA-approved nor on the 503A list for lawful compounding, so there is no legal product to prescribe, online or in person.

References (7 sources)

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.

1.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - telehealth red flags, prescription requirement, and compounded drugs not being FDA-approved.- US Food and Drug Administrationregulatory
2.FDA news release, 6 February 2026: FDA intends to restrict GLP-1 ingredients used in mass-marketed non-approved compounded drugs, and limits marketing claims.- US Food and Drug Administrationregulatory
3.FDA news release, 3 March 2026: warning letters to 30 telehealth companies over claims of sameness and obscured sourcing for compounded GLP-1 drugs.- US Food and Drug Administrationregulatory
4.FDA - Human Drug Compounding: what compounding is, who may lawfully perform it, and that compounded drugs are not FDA-approved.- US Food and Drug Administrationregulatory
5.FDA - Compounding and FDA: Questions and Answers, covering section 503A pharmacy compounding and section 503B outsourcing facilities.- US Food and Drug Administrationregulatory
6.FDA - Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, the three-part test for whether a substance may lawfully go into a compounded drug.- US Food and Drug Administrationregulatory
7.FDA - Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, listing nominated substances - including several research peptides - restricted or withdrawn rather than added to the compounding list.- US Food and Drug Administrationregulatory